Bioversys AG Market Cap ($159.24 Million)
Market Cap & Net Worth: Bioversys AG (BIOV)
Bioversys AG market cap. Bioversys AG (SW:BIOV) has a market capitalization of $159.24 Million (CHF125.96 Million) as of November 3, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #17252 globally and #177 in its home market, demonstrating a -8.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioversys AG's stock price CHF22.50 by its total outstanding shares 5854584 (5.85 Million). Also see BIOV cash flow metrics for how efficiently the company converts equity into cash flow.
Bioversys AG Market Cap History (2025–2026)
Bioversys AG market cap history from 2025 to 2026. Data shows change from $180.60 Million to $166.54 Million (-20.57% CAGR). Check latest Bioversys AG stock price today for real-time trading data and today's change.
Bioversys AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioversys AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Bioversys AG to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
225.75x
Bioversys AG's market cap is 225.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $180.60 Million | $800.00K | -$21.83 Million | 225.75x | N/A |
Competitor Companies of BIOV by Market Capitalization
Companies near Bioversys AG in the global market cap rankings as of November 3, 2026. Also see total assets of Bioversys AG for a full breakdown of the balance sheet.
Key companies related to Bioversys AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Bioversys AG (2025–2026)
Market capitalization of Bioversys AG from 2025 to today. Between 2025 and today, Bioversys AG's market cap moved from $180.60 Million to $ 166.54 Million, with a yearly change of -20.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF166.54 Million | -7.79% |
| 2025 | CHF180.60 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Bioversys AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $159.24 Million USD |
| MoneyControl | $159.24 Million USD |
| MarketWatch | $159.24 Million USD |
| marketcap.company | $159.24 Million USD |
| Reuters | $159.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bioversys AG
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S.… Read more